Intelligence / Healthtech / New Clinical Trials / Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
10 Nov 2026: Trial registered · Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 10 Nov 2026
- Title
- Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy
- Conditions
- Diabetes Mellitus, Type 2
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07929350
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Beijing Supreme Life Pharmaceutical Technology Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Beijing Supreme Life Pharmaceutical Technology Co., Ltd. in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.